Latest News
Takhzyro now available in Newfoundland & Labrador
We love sharing amazing news, and now we have even more to love! On March 17th, 2021, lanadelumab (TAKHZYRO), a subcutaneous monoclonal antibody inhibitor of plasma kallikrein, was
April 6 is the day for HAEGARDA in Canada!
We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, will be included on the Canadian Blood
Takhzyro Added to the NIHB Formulary
We are happy to share that eligible HAE patients across Canada who have coverage under the Non-Insured Health Benefits (NIHB) for First Nations and Inuit Program can now
Takhzyro soon available in Manitoba
Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will list lanadelumab (Takhzyro) as part of Exception Drug Status. To find out more,
Takhzyro is now available in BC
Have you heard the latest fantastic news? British Columbia has recently started providing access to lanadelumab (TAKHZYRO) to eligible HAE patients. For further details and to learn how
Ontario is the latest province to provide access to Takhzyro!
We are excited to share that Ontario is the latest province to provide access to lanadelumab (TAKHZYRO) to HAE patients. When the Ontario Ministry of Health issued its
New Brunswick has added TAKHZYRO to their Provincial Drug Plan!
Another province has added TAKHZYRO to their provincial formulary! As of January 27th, 2021, Type I & II HAE patients in New Brunswick have access to lanadelumab (Takhzyro)
Takeda’s Patient Resource myHAEcheckup.ca is now available!
You deserve to live your best life. However, living with HAE can be difficult, even between attacks. Takeda Inc. is introducing a new, comprehensive resource designed to help
A New CSL Behring Patient Support Program
We wanted to let our members know that starting February 1st, 2021, CSL Behring patient support programs (Hizentra™ CARE Program, and Berinert® Assistance Program) will be streamlined into
Have no fear, the COVID vaccine is safe
Recently, HAE International's President and CEO, Tony Castaldo interviewed Prof. Dr. Marcus Maurer to discuss HAE patients and the COVID vaccine. We encourage everyone to please watch this
TAKHZYRO Now Available in Alberta
We are thrilled to share that as of December 1st, 2020, Type I & II HAE patients in Alberta have access to lanadelumab (Takhzyro) through the province's Drug
TAKHZYRO: One Step Closer
Amazing news! Canadian HAE patients are one step closer to gaining equitable access to the new treatment, TAKHZYRO! After months of negotiations, Takeda Canada announced it has completed
Terrific News for HAE Patients in Quebec
We have some exciting news to share! We are pleased to let everyone know the Institut national d’excellence en santé et en services sociaux (INESSS) has reevaluated lanadelumab
Canada Won the 2020 HAE Global Walk
Thank you to the amazing HAE Community here in Canada - Canada won the Virtual 2020 HAE Global Walk; an annual event organized by the HAE International team.
Great News!
HAEGARDA and TAKHZYRO are now available in Canada. Please talk to your HAE specialist about access. Thank you Canadian Blood Services (CBS) for a very collaborative, informative and
HAE Day 2020
For HAE Day 2020, HAE Canada wants to celebrate! To honour the day we have two BIG announcements: 1) Our website received a facelift! We hope our
Virtual HAE Global Walk
It’s time, once again, for HAE Canada to please ask you to take out your walking shoes and participate in the virtual HAE Global Walk arranged by HAE